Deoxycytidine kinase
From Proteopedia
(Difference between revisions)
| (8 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | <StructureSection load='1p61' size='350' side='right' caption='Mouse deoxycytidine kinase complex with ADP | + | <StructureSection load='1p61' size='350' side='right' caption='Mouse deoxycytidine kinase complex with ADP and deoxycytidine (PDB entry [[1p61]])' scene='54/543346/Cv/1'> |
== Function == | == Function == | ||
| - | '''Deoxycytidine kinase''' (DCK) is required for the phosphorylation of deoxyribonucleosides dC, dG and dA and nucleosides analogs which are used as antiviral and chemotherapeutic agents. <ref>PMID:20614893</ref> | + | '''Deoxycytidine kinase''' (DCK) is required for the phosphorylation of deoxyribonucleosides dC, dG and dA (but not dT and dU) and nucleosides analogs which are used as antiviral and chemotherapeutic agents. <ref>PMID:20614893</ref> |
| + | '''Deoxyadenosine/deoxycytidine kinase''' (DACK) substrates ar cytidine, adenosine, arabinosylcytosine and arabinosyladenine <ref>PMID:6251049</ref>. | ||
== Relevance == | == Relevance == | ||
Deficiency of DCK causes resistance to antiviral and chemotherapeutic agents. | Deficiency of DCK causes resistance to antiviral and chemotherapeutic agents. | ||
| - | </StructureSection> | ||
| - | == 3D Structures of deoxycytidine kinase == | ||
| - | + | == Structural highlights == | |
| - | + | ||
| - | + | The ability of <scene name='54/543346/Cv/4'>DCK to phosphorylate multiple nucleosides arises from the different conformations which the active site glutamic acid can assume</scene> (active site glutamates are in yellow).<ref>PMID:12808445</ref> | |
| - | + | == 3D Structures of deoxycytidine kinase == | |
| - | + | [[Deoxycytidine kinase 3D structures]] | |
| - | + | ||
| - | + | </StructureSection> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | **[[2qrn]] – hDCK + UDP + CMP<br /> | ||
| - | **[[2qro]] – hDCK + UDP + AMP<br /> | ||
| - | **[[3ipx]] – hDCK + ADP + inhibitor<br /> | ||
| - | **[[3ipy]] – hDCK + inhibitor<br /> | ||
| - | **[[3qej]] – hDCK (mutant) + UDP <br /> | ||
| - | **[[4jlj]], [[4jlk]], [[4jlm]], [[4jln]], [[4l5b]], [[4q18]], [[4q19]], [[4q1a]], [[4q1b]], [[4q1c]], [[4q1d]], [[4q1e]], [[4q1f]] - hDCK (mutant) + UDP + inhibitor<br /> | ||
| - | **[[3mjr]] – hDCK + UDP + hydroxyethoxymethylguanine<br /> | ||
| - | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Current revision
| |||||||||||
References
- ↑ Hazra S, Ort S, Konrad M, Lavie A. Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues . Biochemistry. 2010 Aug 10;49(31):6784-90. PMID:20614893 doi:10.1021/bi100839e
- ↑ Møllgaard H. Deoxyadenosine/deoxycytidine kinase from Bacillus subtilis. Purification, characterization, and physiological function. J Biol Chem. 1980 Sep 10;255(17):8216-20 PMID:6251049
- ↑ Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 2003 Jul;10(7):513-9. PMID:12808445 doi:http://dx.doi.org/10.1038/nsb942
